Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2021

Open Access 01-06-2021 | Apixaban | Research Article

Venous thromboembolism prophylaxis in patients undergoing knee replacements: comparison of real-world outcomes

Authors: Syed Shahzad Hasan, Wendy Sunter, Nadia Ahmed, Dalia Dawoud, Syed Tabish Razi Zaidi

Published in: International Journal of Clinical Pharmacy | Issue 3/2021

Login to get access

Abstract

Background Increasing evidence for the use of the aspirin in patients undergoing an orthopaedic surgery for venous thromboembolism prophylaxis has led to a change in the national guidelines substituting anticoagulants with aspirin. Little is known about the impact of such substitution on real-world outcomes from clinical practice. Objective The study was designed to examine clinical outcomes associated with the use of aspirin and apixaban. Setting Two large-scale general hospitals in West Yorkshire region of England. Method A 1-year observational study among adults who underwent elective knee replacements and received venous thromboembolism prophylaxis within the first 14 days post replacements. Main outcome measure The incidence of postoperative venous thromboembolism, leaking wounds during the hospital stay, and 30-day any readmission for the two drugs. Results A total of 420 patients were included. There was a significant drop in apixaban prescribing (from 80.37 to 10.51%) and increase in aspirin use (from 19.02 to 81.71%) after the implementation of the revised guidelines. There were 52 (12.38%) cases of leaking wound, 16 (3.81%) cases of postoperative venous thromboembolism, 45 (10.71%) cases of 30-day readmission and no case of 30-day major bleeding. The leaking wounds and 30-day readmissions were almost twice more frequent in obese compared to non-obese patients. Multivariate logistic regression found an increased risk of leaking wound with apixaban and postoperative venous thromboembolism and 30-day readmission with aspirin use but the differences were not statistically significant. Conclusion The results suggest aspirin to be as effective as apixaban in preventing venous thromboembolism and readmission. Apixaban usage decreased with a corresponding increase in Aspirin use. The impact of obesity and length of hospital stay need further investigations.
Literature
2.
go back to reference Flevas DA, Megaloikonomos PD, Dimopoulos L, Mitsiokapa E, Koulouvaris P, Mavrogenis AF. Thromboembolism prophylaxis in orthopaedics: an update. EFORT Open Rev. 2018;3(4):136–48.CrossRef Flevas DA, Megaloikonomos PD, Dimopoulos L, Mitsiokapa E, Koulouvaris P, Mavrogenis AF. Thromboembolism prophylaxis in orthopaedics: an update. EFORT Open Rev. 2018;3(4):136–48.CrossRef
3.
go back to reference Keller K, Hobohm L, Engelhardt M. Risk of venous thromboembolism after endoprosthetic surgeries: lower versus upper extremity endoprosthetic surgeries. Heart Vessels. 2019;34(5):815–23.CrossRef Keller K, Hobohm L, Engelhardt M. Risk of venous thromboembolism after endoprosthetic surgeries: lower versus upper extremity endoprosthetic surgeries. Heart Vessels. 2019;34(5):815–23.CrossRef
4.
go back to reference Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ. 2013;347:f5133.CrossRef Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ. 2013;347:f5133.CrossRef
5.
go back to reference Sobieraj DM, Coleman CI, Pasupuleti V, Deshpande A, Kaw R, Hernandez AV. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thromb Res. 2015;135(5):888–96.CrossRef Sobieraj DM, Coleman CI, Pasupuleti V, Deshpande A, Kaw R, Hernandez AV. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis. Thromb Res. 2015;135(5):888–96.CrossRef
6.
go back to reference Cohen AT, Hamilton M, Bird A, Mitchell SA, Li S, Horblyuk R, et al. Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS ONE. 2016;11(8):e0160064.CrossRef Cohen AT, Hamilton M, Bird A, Mitchell SA, Li S, Horblyuk R, et al. Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS ONE. 2016;11(8):e0160064.CrossRef
7.
go back to reference Colleoni JL, Ribeiro FN, Mos PAC, Reis JP, de Oliveira HR, Miura BK. Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban. Rev Bras Ortop. 2018;53(1):22–7.CrossRef Colleoni JL, Ribeiro FN, Mos PAC, Reis JP, de Oliveira HR, Miura BK. Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban. Rev Bras Ortop. 2018;53(1):22–7.CrossRef
8.
go back to reference Simes J, Becattini C, Agnelli G, Eikelbook JW, Kirby AC, Mister R, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130(13):1062–71.CrossRef Simes J, Becattini C, Agnelli G, Eikelbook JW, Kirby AC, Mister R, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130(13):1062–71.CrossRef
9.
go back to reference Drescher FS, Sirovich BE, Lee A, Morrison DH, Chiang WH, Larson RJ. Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. J Hosp Med. 2014;9(9):579–85.CrossRef Drescher FS, Sirovich BE, Lee A, Morrison DH, Chiang WH, Larson RJ. Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. J Hosp Med. 2014;9(9):579–85.CrossRef
10.
go back to reference An Vincent VG, Phan K, Levy YD, Bruce WJM. Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty. 2016;31(11):2608–16.CrossRef An Vincent VG, Phan K, Levy YD, Bruce WJM. Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty. 2016;31(11):2608–16.CrossRef
11.
go back to reference Gomez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;14(344):e3675.CrossRef Gomez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;14(344):e3675.CrossRef
13.
go back to reference Lewis S, Glen J, Dawoud D, Dias S, Cobb J, Griffin XL, et al. Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. Lancet Haematol. 2019;6(10):e530–9.CrossRef Lewis S, Glen J, Dawoud D, Dias S, Cobb J, Griffin XL, et al. Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. Lancet Haematol. 2019;6(10):e530–9.CrossRef
14.
go back to reference Dawoud DM, Wonderling D, Glen J, Lewis S, Griffin XL, Hunt BJ, et al. Cost-utility analysis of venous thromboembolism prophylaxis strategies for people undergoing elective total hip and total knee replacement surgeries in the English national health service. Front Pharmacol. 2018;9:1370.CrossRef Dawoud DM, Wonderling D, Glen J, Lewis S, Griffin XL, Hunt BJ, et al. Cost-utility analysis of venous thromboembolism prophylaxis strategies for people undergoing elective total hip and total knee replacement surgeries in the English national health service. Front Pharmacol. 2018;9:1370.CrossRef
17.
go back to reference Galat DD, McGovern SC, Larson DR, Harrington JR, Hanssen AD, Clarke HD. Surgical treatment of early wound complications following primary total knee arthroplasty. J Bone Joint Surg Am. 2009;91(1):48–54.CrossRef Galat DD, McGovern SC, Larson DR, Harrington JR, Hanssen AD, Clarke HD. Surgical treatment of early wound complications following primary total knee arthroplasty. J Bone Joint Surg Am. 2009;91(1):48–54.CrossRef
18.
go back to reference Wagenaar FCBM, Löwik CAM, Zahar A, Jutte PC, Gehrke T, Parvizi J. Persistent wound drainage after total joint arthroplasty: a narrative review. J Arthroplasty. 2019;34(1):175–82.CrossRef Wagenaar FCBM, Löwik CAM, Zahar A, Jutte PC, Gehrke T, Parvizi J. Persistent wound drainage after total joint arthroplasty: a narrative review. J Arthroplasty. 2019;34(1):175–82.CrossRef
19.
go back to reference Jones CW, Spasojevic S, Goh G, Joseph Z, Wood DJ, Yates PJ. Wound discharge after pharmacological thromboprophylaxis in lower limb arthroplasty. J Arthroplasty. 2018;33(1):224–9.CrossRef Jones CW, Spasojevic S, Goh G, Joseph Z, Wood DJ, Yates PJ. Wound discharge after pharmacological thromboprophylaxis in lower limb arthroplasty. J Arthroplasty. 2018;33(1):224–9.CrossRef
20.
go back to reference Garfinkel JH, Gladnick BP, Roland N, Romness DW. Increased incidence of bleeding and wound complications with factor-Xa inhibitors after total joint arthroplasty. J Arthroplasty. 2018;33(2):533–6.CrossRef Garfinkel JH, Gladnick BP, Roland N, Romness DW. Increased incidence of bleeding and wound complications with factor-Xa inhibitors after total joint arthroplasty. J Arthroplasty. 2018;33(2):533–6.CrossRef
21.
go back to reference Marval P, Barker RC. Venous thromboembolism: risks and prevention. Continuing Educ Anaesth Crit Care Pain. 2010;11(1):18–23. Marval P, Barker RC. Venous thromboembolism: risks and prevention. Continuing Educ Anaesth Crit Care Pain. 2010;11(1):18–23.
22.
go back to reference Basques BA, Tetreault MW, Della Valle CJ. Same-day discharge compared with inpatient hospitalization following hip and knee arthroplasty. J Bone Joint Surg Am. 2017;99(23):1969–77.CrossRef Basques BA, Tetreault MW, Della Valle CJ. Same-day discharge compared with inpatient hospitalization following hip and knee arthroplasty. J Bone Joint Surg Am. 2017;99(23):1969–77.CrossRef
23.
go back to reference Adelani MA, Keeney JA, Nunley RM, Clohisy JC, Barrack RL. Readmission following total knee arthroplasty: venous thromboembolism as a “Never Event” is a counterproductive misnomer. J Arthroplasty. 2013;28(5):747–50.CrossRef Adelani MA, Keeney JA, Nunley RM, Clohisy JC, Barrack RL. Readmission following total knee arthroplasty: venous thromboembolism as a “Never Event” is a counterproductive misnomer. J Arthroplasty. 2013;28(5):747–50.CrossRef
24.
go back to reference Penning van-Beest FJA, Overbeek JA, Meijer WM, Woodruff K, van der Vis Jackson J, et al. Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes. Pharmacoepidemiol Drug Saf. 2011;20(9):972–8.CrossRef Penning van-Beest FJA, Overbeek JA, Meijer WM, Woodruff K, van der Vis Jackson J, et al. Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes. Pharmacoepidemiol Drug Saf. 2011;20(9):972–8.CrossRef
25.
go back to reference Lalmohamed A, Vestergaard P, Pouwels S, Klop C, de Boer A, de Vries F. Risk of venous thromboembolism in patients with total hip/knee replacements and matched controls: a population-based cohort study in Denmark. Bone. 2012;50(Supp 1):S186. Lalmohamed A, Vestergaard P, Pouwels S, Klop C, de Boer A, de Vries F. Risk of venous thromboembolism in patients with total hip/knee replacements and matched controls: a population-based cohort study in Denmark. Bone. 2012;50(Supp 1):S186.
26.
go back to reference Lindquist DE, Stewart DW, Brewster A, Waldroup C, Odle BL, Burchette JE, et al. Comparison of postoperative bleeding in total hip and knee arthroplasty patients receiving rivaroxaban, enoxaparin, or aspirin for thromboprophylaxis. Clin Appl Thromb Hemost. 2018;24(8):1315–21.CrossRef Lindquist DE, Stewart DW, Brewster A, Waldroup C, Odle BL, Burchette JE, et al. Comparison of postoperative bleeding in total hip and knee arthroplasty patients receiving rivaroxaban, enoxaparin, or aspirin for thromboprophylaxis. Clin Appl Thromb Hemost. 2018;24(8):1315–21.CrossRef
27.
go back to reference Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013;35(3):312–9.CrossRef Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013;35(3):312–9.CrossRef
28.
go back to reference Pathak R, Karmacharya P, Giri S, Poudel DR, Aryal MR, Bhatt VR, et al. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients. Blood Coagul Fibrinolysis. 2015;26(6):635–42.CrossRef Pathak R, Karmacharya P, Giri S, Poudel DR, Aryal MR, Bhatt VR, et al. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients. Blood Coagul Fibrinolysis. 2015;26(6):635–42.CrossRef
29.
go back to reference Petrucci G, Zaccardi F, Giaretta A, Cavalca V, Capristo E, Cardillo C, et al. Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation. J Thromb Haemost. 2019;17(6):885–95.CrossRef Petrucci G, Zaccardi F, Giaretta A, Cavalca V, Capristo E, Cardillo C, et al. Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation. J Thromb Haemost. 2019;17(6):885–95.CrossRef
Metadata
Title
Venous thromboembolism prophylaxis in patients undergoing knee replacements: comparison of real-world outcomes
Authors
Syed Shahzad Hasan
Wendy Sunter
Nadia Ahmed
Dalia Dawoud
Syed Tabish Razi Zaidi
Publication date
01-06-2021
Publisher
Springer International Publishing
Keyword
Apixaban
Published in
International Journal of Clinical Pharmacy / Issue 3/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01173-3

Other articles of this Issue 3/2021

International Journal of Clinical Pharmacy 3/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.